Loss of heterozygosity in the RAD51 and BRCA2 regions in breast cancer

被引:3
作者
Nowacka-Zawisza, Maria [1 ]
Brys, Magdalena [1 ]
Romanowicz-Makowska, Hanna [2 ]
Kulig, Andrzej [2 ]
Krajewska, Wanda M. [1 ]
机构
[1] Univ Lodz, Dept Cytobiochem, PL-90237 Lodz, Poland
[2] Polish Mothers Mem Hosp, Dept Clin Pathomorphol, Res Inst, Lodz, Poland
来源
CANCER DETECTION AND PREVENTION | 2008年 / 32卷 / 02期
关键词
RAD51; BRCA2; loss of heterozygosity (LOH); breast cancer; microsatelite markers; clinicopathological parameters; heterozygous alleles;
D O I
10.1016/j.cdp.2008.06.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Loss of heterozygosity (LOH) in the 5q14-21 and 13q12-13 regions can contribute to the inactivation of RAD51 and BRCA2 genes implicated in the pathogenesis of breast cancer. We investigated allelic losses in rnicrosatellites in the RAD51 and BRCA2 regions, and their association with clinicopathological parameters in breast cancer. Methods: The LOH analysis was performed by amplifying DNA by PCR, using D15S118, D15S214, D15S1006 polymorphic markers in the 15q14-21 region and D13S260, D13S290 polymorphic markers in the 13q12-13 region in 36 sporadic breast cancer cases. Results: LOH in the RAD51 region ranged from 29% to 46% and in the BRCA2 region from 38% to 43% of informative cases. Eleven percent of the breast cancer cases displayed LOH for at least one studied marker in the RAD51 region exclusively. On the other hand, 44% of cases manifested statistically significant LOH for at least one microsatellite marker concomitantly in the RAD51 and BRCA2 regions. LOH in the RAD51 region similarly as in the BRCA2 region appeared to correlate with steroid receptors content and lymph node status. Discussion: The obtained results indicate that alteration in RAD51 region may contribute to the disturbances of DNA repair involving RAD51 and/or BRCA2 penetration and thus enhance the risk of breast cancer development. (C) 2008 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:144 / 148
页数:5
相关论文
共 40 条
  • [1] Balsara BR, 1999, CANCER RES, V59, P450
  • [2] Blasiak J, 2003, ACTA BIOCHIM POL, V50, P249
  • [3] Internal repeats in the BRCA2 protein sequence
    Bork, P
    Blomberg, N
    Nilges, M
    [J]. NATURE GENETICS, 1996, 13 (01) : 22 - 23
  • [4] RAPID DETECTION OF ALLELE LOSS IN COLORECTAL TUMORS USING MICROSATELLITES AND FLUORESCENT DNA TECHNOLOGY
    CAWKWELL, L
    BELL, SM
    LEWIS, FA
    DIXON, MF
    TAYLOR, GR
    QUIRKE, P
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (06) : 1262 - 1267
  • [5] Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer
    Charef-Hamza, S
    Trimeche, M
    Ziadi, S
    Amara, K
    Gaddas, N
    Mokni, M
    Sriha, B
    Yacoubi, T
    Korbi, S
    [J]. CANCER LETTERS, 2005, 224 (02) : 185 - 191
  • [6] The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment
    Chen, PL
    Chen, CF
    Chen, YM
    Xiao, J
    Sharp, ZD
    Lee, WH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) : 5287 - 5292
  • [7] LOSS OF HETEROZYGOSITY IN SPORADIC BREAST-TUMORS AT THE BRCA2 LOCUS ON CHROMOSOME 13Q12-Q13
    CLETONJANSEN, AM
    COLLINS, N
    LAKHANI, SR
    WEISSENBACH, J
    DEVILEE, P
    CORNELISSE, CJ
    STRATTON, MR
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (05) : 1241 - 1244
  • [8] Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma
    De Rienzo, A
    Balsara, BR
    Apostolou, S
    Jhanwar, SC
    Testa, JR
    [J]. ONCOGENE, 2001, 20 (43) : 6245 - 6249
  • [9] Mapping lass of heterozygosity at chromosome 13q:: Loss at 13q12-q13 is associated with breast tumour progression and poor prognosis
    Eiriksdottir, G
    Johannesdottir, G
    Ingvarsson, S
    Björnsdottir, IB
    Jonasson, JG
    Agnarsson, BA
    Hallgrimsson, J
    Gudmundsson, J
    Egilsson, V
    Sigurdsson, H
    Barkardottir, RB
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (13) : 2076 - 2081
  • [10] Foster KA, 1996, CANCER RES, V56, P3622